The therapeutic potential of compounds that boosted the ISR showed corrective activity in cell and animal models of DYT-TOR1A (Caffall et al., 2021), further indicating that therapeutic manipulation of the eIF2α pathway could be beneficial for dystonia patients. This evidence concerns the gene EIF2A and Dystonia.